顶部logo
顶部logo
more_1

home

ホーム > レポート一覧 > ジェネリック注射剤の世界市場規模、シェア、企業ランキング、売上、需要動向予測（2025～2031年）

ジェネリック注射剤の世界市場規模、シェア、企業ランキング、売上、需要動向予測（2025～2031年）

Generic Injectables - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
  • レポートID：
    3461
  • 発表時期：
    2025-01-17
  • レポート形式：
    PDF
  • 産業カテゴリー：
    医療関係技術およびそのサービス
  • レポート言語：
    英語、日本語
  • ページ数：
    110
  • 発行会社（調査会社）：
    QYResearch
title

言語とエディションの価格

  • 英語版
  • 日本語版
  • 英語と日本語版

個人版詳細

マルチユーザー版詳細

企業版詳細

  • 英語版
  • 日本語版
  • 英語と日本語版

価格表記: USDを日本円(税抜)に換算，本日の銀行送金レート: 1USD=162.40円。

※米ドル表示価格+10％消費税。

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

title

レポートの概要

本報告書は、世界のジェネリック注射剤市場について包括的な分析を行い、市場全体の動向を明らかにすることを目的としています。売上高に加え、主要企業の市場シェアおよび順位を整理し、市場構造を多角的に把握します。さらに、地域・国別、製品タイプ別、用途分野別などの観点からジェネリック注射剤市場を分析し、需要構造と成長特性を明確化します。
ジェネリック注射剤市場の規模、推定値および予測は、2025年を基準年とし、2021年から2032年までの期間における売上高に基づいて提示しています。定量分析と定性分析を組み合わせることで、ビジネスおよび成長戦略を検討し、市場競争環境を評価し、企業の市場ポジションを把握した上で、ジェネリック注射剤に関する的確な意思決定を行うための実践的なインサイトを提供します。
 主要ジェネリック注射剤市場の統計
2025年世界市場規模：32770百万米ドル
2026年世界市場規模：33810百万米ドル
2032年予測市場規模：41560百万米ドル
2026–2032年予測期間CAGR：3.5%
本レポートはジェネリック注射剤市場の中長期的な成長動向を定量分析および定性分析の両面から体系的に整理しています。 
【市場セグメンテーション】
主要企業・競争環境
ジェネリック注射剤市場の主要企業には以下が含まれます：
Hospira (Pfizer Inc.)
Fresenius Kabi
Sandoz (Novartis)
Hikma Pharmaceuticals PLC
Dr. Reddy’s Laboratories Ltd
Grifols
Nichi-Iko Group (Sagent)
Teva Pharmaceutical
Auromedics
Sanofi
Gland Pharma
Endo International PLC 

製品別
Small Molecule
Large Molecule 

アプリケーション別
Oncology
Anesthesia
Anti-Infectives
Parenteral Nutrition
Cardiovascular Diseases 

レポート対象地域
北米：アメリカ、カナダ、その他
アジア太平洋：中国、日本、韓国、東南アジア、インド、オーストラリア、その他
ヨーロッパ：ドイツ、フランス、イギリス、イタリア、オランダ、北欧諸国、その他
ラテンアメリカ：メキシコ、ブラジル、その他
中東・アフリカ：トルコ、サウジアラビア、UAE、その他
レポート構成（章別概要）
第1章｜市場概要と成長展望
ジェネリック注射剤市場の全体像を整理し、市場規模、売上予測を体系的に解説します。同時に成長要因、市場機会、業界課題、リスク要因を分析し、中長期的な市場展望を提示します
第2章｜主要企業の競争分析
ジェネリック注射剤市場における主要プレイヤー（トップ5社・トップ10社）を対象に、売上高、製造拠点、製品構成、市場シェアを多面的に分析し、競争構造を明確化します
第3章｜製品カテゴリ別市場動向
製品タイプ別にジェネリック注射剤市場を分類し、売上高、市場シェアを分析します。成長性の高い製品分野と市場構造の変化を明らかにします
第4章｜用途別市場動向
用途別にジェネリック注射剤市場規模、売上高、市場シェアを整理し、業界別の需要動向と成長ポテンシャルを分析します
第5章｜地域別市場分析
地域別の市場成長率、売上高を詳細に分析し、ジェネリック注射剤市場の地理的需要構造を可視化します。各地域の市場規模推移と将来の成長余地を評価します。
第6章｜国別市場動向
主要国・地域ごとに、ジェネリック注射剤市場の売上高、成長要因、政策・規制環境、競争特性を整理し、国別市場の特徴を明確にします
第7章｜主要企業プロファイル
ジェネリック注射剤市場を牽引する主要企業について、売上高、粗利益率、製品ポートフォリオ、最新の戦略動向を詳細に解説します
第8章｜バリューチェーンと市場構造分析
業界全体のサプライチェーンを上流から下流まで整理し、コスト構造や流通モデルの動向を分析します
第9章｜調査結果
調査結果を総括し、市場全体のトレンド、今後の成長機会、潜在的リスク、戦略的な洞察を提示します
第10章｜付録（調査手法・データソース）
調査設計、分析手法、使用データソースの詳細を明示し、レポートの信頼性と透明性を担保します

本レポートの要点と洞察
●ジェネリック注射剤市場の全体像と成長見通し
ジェネリック注射剤市場の規模変化の傾向、成長予測及び需要動向を体系的に整理いたします。2021年から2025年までの実績データに基づき、2032年までの中長期予測を提示し、市場の拡大速度と成長潜在力を明らかにします。同時に、最近の関税調整措置など各国の政策動向を踏まえ、多角的にグローバル経済環境がジェネリック注射剤市場に与える影響を分析いたします。
●市場環境の構成要素とマクロトレンド
ジェネリック注射剤産業を取り巻く市場環境について、需要構造の変化、政策対応、技術革新の進展といった主要要因を整理します。特に、国際貿易政策や関税政策の変化が企業戦略に及ぼす影響、サプライチェーン再編の動きと事業運営への波及効果を明確化し、市場環境の全体像を包括的に提示します。
●競争構造と主要企業の動向分析
ジェネリック注射剤市場における主要企業の売上規模、市場シェア、競争ポジションを整理し、競争構造の特徴を分析します。各社の競争戦略、事業拡大の方向性、新製品・新技術の投入動向を通じて、技術革新が市場競争に与える影響と競争環境の変化を解読します。
●競争環境と事業動向の把握
製品タイプ別、用途別、地域・国別の観点からジェネリック注射剤市場のセグメント構造を整理します。各地域の需要構成と成長特性を比較分析し、各細分領域が市場全体の成長に与える貢献度と相互関連性を明確にします。
●成長要因・課題・リスクの分析
ジェネリック注射剤市場の成長を支える主要ドライバーを整理するとともに、業界特有の課題や潜在的リスクを分析します。原材料調達、供給システム、事業運営における不確実性を踏まえ、サプライチェーン及び事業レジリエンス強化の方向性についても考察します。
●将来トレンドと市場展望
ジェネリック注射剤市場の中長期的な成長トレンドと将来の発展シナリオを提示します。持続的成長を実現するための重要な成功要因を整理し、今後の市場参入企業や既存プレイヤーの戦略的意思決定に参考となる視点を提供いたします。
title

Description

The global market for Generic Injectables was estimated to be worth US$ 32770 million in 2024 and is forecast to a readjusted size of US$ 41560 million by 2031 with a CAGR of 3.5% during the forecast period 2025-2031.

Generic injectables refer to sterile solutions (including emulsions and suspensions) made of drugs for injection into the body, and sterile powders or concentrated solutions that are prepared into solutions or suspensions before use.
The injection is fast and reliable, not affected by pH, enzymes, food, etc., has no first-pass effect, and can play a systemic or local positioning effect. It is suitable for patients who are not suitable for oral medicine and patients who cannot be taken orally. However, the development and production process of injections is complicated and safe. The body has poor adaptability and high cost.

In the segment of generic sterile injectables, the Hospira (Pfizer Inc.) is the largest player, and Fresenius Kabi is the second. Top two players hold a share about 27% in 2019. The US market is dominated by two players like Hospira (Pfizer Inc.), Fresenius Kabi, Sandoz (Novartis), Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories Ltd, Grifols, Nichi-Iko Group (Sagent), Teva Pharmaceutical, Auromedics, Sanofi, Gland Pharma and Endo International PLC.

This report aims to provide a comprehensive presentation of the global market for Generic Injectables, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Generic Injectables by region & country, by Type, and by Application.

The Generic Injectables market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Generic Injectables.

Market Segmentation
By Company
    Hospira (Pfizer Inc.)
    Fresenius Kabi
    Sandoz (Novartis)
    Hikma Pharmaceuticals PLC
    Dr. Reddy’s Laboratories Ltd
    Grifols
    Nichi-Iko Group (Sagent)
    Teva Pharmaceutical
    Auromedics
    Sanofi
    Gland Pharma
    Endo International PLC

Segment by Type
    Small Molecule
    Large Molecule

Segment by Application
    Oncology
    Anesthesia
    Anti-Infectives
    Parenteral Nutrition
    Cardiovascular Diseases

By Region
    North America
        United States
        Canada
    Asia-Pacific
        China
        Japan
        South Korea
        Southeast Asia
        India
        Australia
        Rest of Asia-Pacific
    Europe
        Germany
        France
        U.K.
        Italy
        Netherlands
        Nordic Countries
        Rest of Europe
    Latin America
        Mexico
        Brazil
        Rest of Latin America
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE
        Rest of MEA

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Generic Injectables company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Generic Injectables in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Generic Injectables in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
title

Table of Contents

1 Market Overview
    1.1 Generic Injectables Product Introduction
    1.2 Global Generic Injectables Market Size Forecast (2020-2031)
    1.3 Generic Injectables Market Trends & Drivers
        1.3.1 Generic Injectables Industry Trends
        1.3.2 Generic Injectables Market Drivers & Opportunity
        1.3.3 Generic Injectables Market Challenges
        1.3.4 Generic Injectables Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered
2 Competitive Analysis by Company
    2.1 Global Generic Injectables Players Revenue Ranking (2024)
    2.2 Global Generic Injectables Revenue by Company (2020-2025)
    2.3 Key Companies Generic Injectables Manufacturing Base Distribution and Headquarters
    2.4 Key Companies Generic Injectables Product Offered
    2.5 Key Companies Time to Begin Mass Production of Generic Injectables
    2.6 Generic Injectables Market Competitive Analysis
        2.6.1 Generic Injectables Market Concentration Rate (2020-2025)
        2.6.2 Global 5 and 10 Largest Companies by Generic Injectables Revenue in 2024
        2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Generic Injectables as of 2024)
    2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Small Molecule
        3.1.2 Large Molecule
    3.2 Global Generic Injectables Sales Value by Type
        3.2.1 Global Generic Injectables Sales Value by Type (2020 VS 2024 VS 2031)
        3.2.2 Global Generic Injectables Sales Value, by Type (2020-2031)
        3.2.3 Global Generic Injectables Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Oncology
        4.1.2 Anesthesia
        4.1.3 Anti-Infectives
        4.1.4 Parenteral Nutrition
        4.1.5 Cardiovascular Diseases
    4.2 Global Generic Injectables Sales Value by Application
        4.2.1 Global Generic Injectables Sales Value by Application (2020 VS 2024 VS 2031)
        4.2.2 Global Generic Injectables Sales Value, by Application (2020-2031)
        4.2.3 Global Generic Injectables Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
    5.1 Global Generic Injectables Sales Value by Region
        5.1.1 Global Generic Injectables Sales Value by Region: 2020 VS 2024 VS 2031
        5.1.2 Global Generic Injectables Sales Value by Region (2020-2025)
        5.1.3 Global Generic Injectables Sales Value by Region (2026-2031)
        5.1.4 Global Generic Injectables Sales Value by Region (%), (2020-2031)
    5.2 North America
        5.2.1 North America Generic Injectables Sales Value, 2020-2031
        5.2.2 North America Generic Injectables Sales Value by Country (%), 2024 VS 2031
    5.3 Europe
        5.3.1 Europe Generic Injectables Sales Value, 2020-2031
        5.3.2 Europe Generic Injectables Sales Value by Country (%), 2024 VS 2031
    5.4 Asia Pacific
        5.4.1 Asia Pacific Generic Injectables Sales Value, 2020-2031
        5.4.2 Asia Pacific Generic Injectables Sales Value by Region (%), 2024 VS 2031
    5.5 South America
        5.5.1 South America Generic Injectables Sales Value, 2020-2031
        5.5.2 South America Generic Injectables Sales Value by Country (%), 2024 VS 2031
    5.6 Middle East & Africa
        5.6.1 Middle East & Africa Generic Injectables Sales Value, 2020-2031
        5.6.2 Middle East & Africa Generic Injectables Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Generic Injectables Sales Value Growth Trends, 2020 VS 2024 VS 2031
    6.2 Key Countries/Regions Generic Injectables Sales Value, 2020-2031
    6.3 United States
        6.3.1 United States Generic Injectables Sales Value, 2020-2031
        6.3.2 United States Generic Injectables Sales Value by Type (%), 2024 VS 2031
        6.3.3 United States Generic Injectables Sales Value by Application, 2024 VS 2031
    6.4 Europe
        6.4.1 Europe Generic Injectables Sales Value, 2020-2031
        6.4.2 Europe Generic Injectables Sales Value by Type (%), 2024 VS 2031
        6.4.3 Europe Generic Injectables Sales Value by Application, 2024 VS 2031
    6.5 China
        6.5.1 China Generic Injectables Sales Value, 2020-2031
        6.5.2 China Generic Injectables Sales Value by Type (%), 2024 VS 2031
        6.5.3 China Generic Injectables Sales Value by Application, 2024 VS 2031
    6.6 Japan
        6.6.1 Japan Generic Injectables Sales Value, 2020-2031
        6.6.2 Japan Generic Injectables Sales Value by Type (%), 2024 VS 2031
        6.6.3 Japan Generic Injectables Sales Value by Application, 2024 VS 2031
    6.7 South Korea
        6.7.1 South Korea Generic Injectables Sales Value, 2020-2031
        6.7.2 South Korea Generic Injectables Sales Value by Type (%), 2024 VS 2031
        6.7.3 South Korea Generic Injectables Sales Value by Application, 2024 VS 2031
    6.8 Southeast Asia
        6.8.1 Southeast Asia Generic Injectables Sales Value, 2020-2031
        6.8.2 Southeast Asia Generic Injectables Sales Value by Type (%), 2024 VS 2031
        6.8.3 Southeast Asia Generic Injectables Sales Value by Application, 2024 VS 2031
    6.9 India
        6.9.1 India Generic Injectables Sales Value, 2020-2031
        6.9.2 India Generic Injectables Sales Value by Type (%), 2024 VS 2031
        6.9.3 India Generic Injectables Sales Value by Application, 2024 VS 2031
7 Company Profiles
    7.1 Hospira (Pfizer Inc.)
        7.1.1 Hospira (Pfizer Inc.) Profile
        7.1.2 Hospira (Pfizer Inc.) Main Business
        7.1.3 Hospira (Pfizer Inc.) Generic Injectables Products, Services and Solutions
        7.1.4 Hospira (Pfizer Inc.) Generic Injectables Revenue (US$ Million) & (2020-2025)
        7.1.5 Hospira (Pfizer Inc.) Recent Developments
    7.2 Fresenius Kabi
        7.2.1 Fresenius Kabi Profile
        7.2.2 Fresenius Kabi Main Business
        7.2.3 Fresenius Kabi Generic Injectables Products, Services and Solutions
        7.2.4 Fresenius Kabi Generic Injectables Revenue (US$ Million) & (2020-2025)
        7.2.5 Fresenius Kabi Recent Developments
    7.3 Sandoz (Novartis)
        7.3.1 Sandoz (Novartis) Profile
        7.3.2 Sandoz (Novartis) Main Business
        7.3.3 Sandoz (Novartis) Generic Injectables Products, Services and Solutions
        7.3.4 Sandoz (Novartis) Generic Injectables Revenue (US$ Million) & (2020-2025)
        7.3.5 Sandoz (Novartis) Recent Developments
    7.4 Hikma Pharmaceuticals PLC
        7.4.1 Hikma Pharmaceuticals PLC Profile
        7.4.2 Hikma Pharmaceuticals PLC Main Business
        7.4.3 Hikma Pharmaceuticals PLC Generic Injectables Products, Services and Solutions
        7.4.4 Hikma Pharmaceuticals PLC Generic Injectables Revenue (US$ Million) & (2020-2025)
        7.4.5 Hikma Pharmaceuticals PLC Recent Developments
    7.5 Dr. Reddy’s Laboratories Ltd
        7.5.1 Dr. Reddy’s Laboratories Ltd Profile
        7.5.2 Dr. Reddy’s Laboratories Ltd Main Business
        7.5.3 Dr. Reddy’s Laboratories Ltd Generic Injectables Products, Services and Solutions
        7.5.4 Dr. Reddy’s Laboratories Ltd Generic Injectables Revenue (US$ Million) & (2020-2025)
        7.5.5 Dr. Reddy’s Laboratories Ltd Recent Developments
    7.6 Grifols
        7.6.1 Grifols Profile
        7.6.2 Grifols Main Business
        7.6.3 Grifols Generic Injectables Products, Services and Solutions
        7.6.4 Grifols Generic Injectables Revenue (US$ Million) & (2020-2025)
        7.6.5 Grifols Recent Developments
    7.7 Nichi-Iko Group (Sagent)
        7.7.1 Nichi-Iko Group (Sagent) Profile
        7.7.2 Nichi-Iko Group (Sagent) Main Business
        7.7.3 Nichi-Iko Group (Sagent) Generic Injectables Products, Services and Solutions
        7.7.4 Nichi-Iko Group (Sagent) Generic Injectables Revenue (US$ Million) & (2020-2025)
        7.7.5 Nichi-Iko Group (Sagent) Recent Developments
    7.8 Teva Pharmaceutical
        7.8.1 Teva Pharmaceutical Profile
        7.8.2 Teva Pharmaceutical Main Business
        7.8.3 Teva Pharmaceutical Generic Injectables Products, Services and Solutions
        7.8.4 Teva Pharmaceutical Generic Injectables Revenue (US$ Million) & (2020-2025)
        7.8.5 Teva Pharmaceutical Recent Developments
    7.9 Auromedics
        7.9.1 Auromedics Profile
        7.9.2 Auromedics Main Business
        7.9.3 Auromedics Generic Injectables Products, Services and Solutions
        7.9.4 Auromedics Generic Injectables Revenue (US$ Million) & (2020-2025)
        7.9.5 Auromedics Recent Developments
    7.10 Sanofi
        7.10.1 Sanofi Profile
        7.10.2 Sanofi Main Business
        7.10.3 Sanofi Generic Injectables Products, Services and Solutions
        7.10.4 Sanofi Generic Injectables Revenue (US$ Million) & (2020-2025)
        7.10.5 Sanofi Recent Developments
    7.11 Gland Pharma
        7.11.1 Gland Pharma Profile
        7.11.2 Gland Pharma Main Business
        7.11.3 Gland Pharma Generic Injectables Products, Services and Solutions
        7.11.4 Gland Pharma Generic Injectables Revenue (US$ Million) & (2020-2025)
        7.11.5 Gland Pharma Recent Developments
    7.12 Endo International PLC
        7.12.1 Endo International PLC Profile
        7.12.2 Endo International PLC Main Business
        7.12.3 Endo International PLC Generic Injectables Products, Services and Solutions
        7.12.4 Endo International PLC Generic Injectables Revenue (US$ Million) & (2020-2025)
        7.12.5 Endo International PLC Recent Developments
8 Industry Chain Analysis
    8.1 Generic Injectables Industrial Chain
    8.2 Generic Injectables Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Generic Injectables Sales Model
        8.5.2 Sales Channel
        8.5.3 Generic Injectables Distributors
9 Research Findings and Conclusion
10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
            10.1.1.1 Research Programs/Design
            10.1.1.2 Market Size Estimation
            10.1.1.3 Market Breakdown and Data Triangulation
        10.1.2 Data Source
            10.1.2.1 Secondary Sources
            10.1.2.2 Primary Sources
    10.2 Author Details
    10.3 Disclaimer
title

Table of Figures

List of Tables
 Table 1. Generic Injectables Market Trends
 Table 2. Generic Injectables Market Drivers & Opportunity
 Table 3. Generic Injectables Market Challenges
 Table 4. Generic Injectables Market Restraints
 Table 5. Global Generic Injectables Revenue by Company (2020-2025) & (US$ Million)
 Table 6. Global Generic Injectables Revenue Market Share by Company (2020-2025)
 Table 7. Key Companies Generic Injectables Manufacturing Base Distribution and Headquarters
 Table 8. Key Companies Generic Injectables Product Type
 Table 9. Key Companies Time to Begin Mass Production of Generic Injectables
 Table 10. Global Generic Injectables Companies Market Concentration Ratio (CR5 and HHI)
 Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Generic Injectables as of 2024)
 Table 12. Mergers & Acquisitions, Expansion Plans
 Table 13. Global Generic Injectables Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
 Table 14. Global Generic Injectables Sales Value by Type (2020-2025) & (US$ Million)
 Table 15. Global Generic Injectables Sales Value by Type (2026-2031) & (US$ Million)
 Table 16. Global Generic Injectables Sales Market Share in Value by Type (2020-2025)
 Table 17. Global Generic Injectables Sales Market Share in Value by Type (2026-2031)
 Table 18. Global Generic Injectables Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
 Table 19. Global Generic Injectables Sales Value by Application (2020-2025) & (US$ Million)
 Table 20. Global Generic Injectables Sales Value by Application (2026-2031) & (US$ Million)
 Table 21. Global Generic Injectables Sales Market Share in Value by Application (2020-2025)
 Table 22. Global Generic Injectables Sales Market Share in Value by Application (2026-2031)
 Table 23. Global Generic Injectables Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
 Table 24. Global Generic Injectables Sales Value by Region (2020-2025) & (US$ Million)
 Table 25. Global Generic Injectables Sales Value by Region (2026-2031) & (US$ Million)
 Table 26. Global Generic Injectables Sales Value by Region (2020-2025) & (%)
 Table 27. Global Generic Injectables Sales Value by Region (2026-2031) & (%)
 Table 28. Key Countries/Regions Generic Injectables Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
 Table 29. Key Countries/Regions Generic Injectables Sales Value, (2020-2025) & (US$ Million)
 Table 30. Key Countries/Regions Generic Injectables Sales Value, (2026-2031) & (US$ Million)
 Table 31. Hospira (Pfizer Inc.) Basic Information List
 Table 32. Hospira (Pfizer Inc.) Description and Business Overview
 Table 33. Hospira (Pfizer Inc.) Generic Injectables Products, Services and Solutions
 Table 34. Revenue (US$ Million) in Generic Injectables Business of Hospira (Pfizer Inc.) (2020-2025)
 Table 35. Hospira (Pfizer Inc.) Recent Developments
 Table 36. Fresenius Kabi Basic Information List
 Table 37. Fresenius Kabi Description and Business Overview
 Table 38. Fresenius Kabi Generic Injectables Products, Services and Solutions
 Table 39. Revenue (US$ Million) in Generic Injectables Business of Fresenius Kabi (2020-2025)
 Table 40. Fresenius Kabi Recent Developments
 Table 41. Sandoz (Novartis) Basic Information List
 Table 42. Sandoz (Novartis) Description and Business Overview
 Table 43. Sandoz (Novartis) Generic Injectables Products, Services and Solutions
 Table 44. Revenue (US$ Million) in Generic Injectables Business of Sandoz (Novartis) (2020-2025)
 Table 45. Sandoz (Novartis) Recent Developments
 Table 46. Hikma Pharmaceuticals PLC Basic Information List
 Table 47. Hikma Pharmaceuticals PLC Description and Business Overview
 Table 48. Hikma Pharmaceuticals PLC Generic Injectables Products, Services and Solutions
 Table 49. Revenue (US$ Million) in Generic Injectables Business of Hikma Pharmaceuticals PLC (2020-2025)
 Table 50. Hikma Pharmaceuticals PLC Recent Developments
 Table 51. Dr. Reddy’s Laboratories Ltd Basic Information List
 Table 52. Dr. Reddy’s Laboratories Ltd Description and Business Overview
 Table 53. Dr. Reddy’s Laboratories Ltd Generic Injectables Products, Services and Solutions
 Table 54. Revenue (US$ Million) in Generic Injectables Business of Dr. Reddy’s Laboratories Ltd (2020-2025)
 Table 55. Dr. Reddy’s Laboratories Ltd Recent Developments
 Table 56. Grifols Basic Information List
 Table 57. Grifols Description and Business Overview
 Table 58. Grifols Generic Injectables Products, Services and Solutions
 Table 59. Revenue (US$ Million) in Generic Injectables Business of Grifols (2020-2025)
 Table 60. Grifols Recent Developments
 Table 61. Nichi-Iko Group (Sagent) Basic Information List
 Table 62. Nichi-Iko Group (Sagent) Description and Business Overview
 Table 63. Nichi-Iko Group (Sagent) Generic Injectables Products, Services and Solutions
 Table 64. Revenue (US$ Million) in Generic Injectables Business of Nichi-Iko Group (Sagent) (2020-2025)
 Table 65. Nichi-Iko Group (Sagent) Recent Developments
 Table 66. Teva Pharmaceutical Basic Information List
 Table 67. Teva Pharmaceutical Description and Business Overview
 Table 68. Teva Pharmaceutical Generic Injectables Products, Services and Solutions
 Table 69. Revenue (US$ Million) in Generic Injectables Business of Teva Pharmaceutical (2020-2025)
 Table 70. Teva Pharmaceutical Recent Developments
 Table 71. Auromedics Basic Information List
 Table 72. Auromedics Description and Business Overview
 Table 73. Auromedics Generic Injectables Products, Services and Solutions
 Table 74. Revenue (US$ Million) in Generic Injectables Business of Auromedics (2020-2025)
 Table 75. Auromedics Recent Developments
 Table 76. Sanofi Basic Information List
 Table 77. Sanofi Description and Business Overview
 Table 78. Sanofi Generic Injectables Products, Services and Solutions
 Table 79. Revenue (US$ Million) in Generic Injectables Business of Sanofi (2020-2025)
 Table 80. Sanofi Recent Developments
 Table 81. Gland Pharma Basic Information List
 Table 82. Gland Pharma Description and Business Overview
 Table 83. Gland Pharma Generic Injectables Products, Services and Solutions
 Table 84. Revenue (US$ Million) in Generic Injectables Business of Gland Pharma (2020-2025)
 Table 85. Gland Pharma Recent Developments
 Table 86. Endo International PLC Basic Information List
 Table 87. Endo International PLC Description and Business Overview
 Table 88. Endo International PLC Generic Injectables Products, Services and Solutions
 Table 89. Revenue (US$ Million) in Generic Injectables Business of Endo International PLC (2020-2025)
 Table 90. Endo International PLC Recent Developments
 Table 91. Key Raw Materials Lists
 Table 92. Raw Materials Key Suppliers Lists
 Table 93. Generic Injectables Downstream Customers
 Table 94. Generic Injectables Distributors List
 Table 95. Research Programs/Design for This Report
 Table 96. Key Data Information from Secondary Sources
 Table 97. Key Data Information from Primary Sources
 Table 98. Business Unit and Senior & Team Lead Analysts


List of Figures
 Figure 1. Generic Injectables Product Picture
 Figure 2. Global Generic Injectables Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Global Generic Injectables Sales Value (2020-2031) & (US$ Million)
 Figure 4. Generic Injectables Report Years Considered
 Figure 5. Global Generic Injectables Players Revenue Ranking (2024) & (US$ Million)
 Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Generic Injectables Revenue in 2024
 Figure 7. Generic Injectables Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 8. Small Molecule Picture
 Figure 9. Large Molecule Picture
 Figure 10. Global Generic Injectables Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
 Figure 11. Global Generic Injectables Sales Value Market Share by Type, 2024 & 2031
 Figure 12. Product Picture of Oncology
 Figure 13. Product Picture of Anesthesia
 Figure 14. Product Picture of Anti-Infectives
 Figure 15. Product Picture of Parenteral Nutrition
 Figure 16. Product Picture of Cardiovascular Diseases
 Figure 17. Global Generic Injectables Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
 Figure 18. Global Generic Injectables Sales Value Market Share by Application, 2024 & 2031
 Figure 19. North America Generic Injectables Sales Value (2020-2031) & (US$ Million)
 Figure 20. North America Generic Injectables Sales Value by Country (%), 2024 VS 2031
 Figure 21. Europe Generic Injectables Sales Value, (2020-2031) & (US$ Million)
 Figure 22. Europe Generic Injectables Sales Value by Country (%), 2024 VS 2031
 Figure 23. Asia Pacific Generic Injectables Sales Value, (2020-2031) & (US$ Million)
 Figure 24. Asia Pacific Generic Injectables Sales Value by Region (%), 2024 VS 2031
 Figure 25. South America Generic Injectables Sales Value, (2020-2031) & (US$ Million)
 Figure 26. South America Generic Injectables Sales Value by Country (%), 2024 VS 2031
 Figure 27. Middle East & Africa Generic Injectables Sales Value, (2020-2031) & (US$ Million)
 Figure 28. Middle East & Africa Generic Injectables Sales Value by Country (%), 2024 VS 2031
 Figure 29. Key Countries/Regions Generic Injectables Sales Value (%), (2020-2031)
 Figure 30. United States Generic Injectables Sales Value, (2020-2031) & (US$ Million)
 Figure 31. United States Generic Injectables Sales Value by Type (%), 2024 VS 2031
 Figure 32. United States Generic Injectables Sales Value by Application (%), 2024 VS 2031
 Figure 33. Europe Generic Injectables Sales Value, (2020-2031) & (US$ Million)
 Figure 34. Europe Generic Injectables Sales Value by Type (%), 2024 VS 2031
 Figure 35. Europe Generic Injectables Sales Value by Application (%), 2024 VS 2031
 Figure 36. China Generic Injectables Sales Value, (2020-2031) & (US$ Million)
 Figure 37. China Generic Injectables Sales Value by Type (%), 2024 VS 2031
 Figure 38. China Generic Injectables Sales Value by Application (%), 2024 VS 2031
 Figure 39. Japan Generic Injectables Sales Value, (2020-2031) & (US$ Million)
 Figure 40. Japan Generic Injectables Sales Value by Type (%), 2024 VS 2031
 Figure 41. Japan Generic Injectables Sales Value by Application (%), 2024 VS 2031
 Figure 42. South Korea Generic Injectables Sales Value, (2020-2031) & (US$ Million)
 Figure 43. South Korea Generic Injectables Sales Value by Type (%), 2024 VS 2031
 Figure 44. South Korea Generic Injectables Sales Value by Application (%), 2024 VS 2031
 Figure 45. Southeast Asia Generic Injectables Sales Value, (2020-2031) & (US$ Million)
 Figure 46. Southeast Asia Generic Injectables Sales Value by Type (%), 2024 VS 2031
 Figure 47. Southeast Asia Generic Injectables Sales Value by Application (%), 2024 VS 2031
 Figure 48. India Generic Injectables Sales Value, (2020-2031) & (US$ Million)
 Figure 49. India Generic Injectables Sales Value by Type (%), 2024 VS 2031
 Figure 50. India Generic Injectables Sales Value by Application (%), 2024 VS 2031
 Figure 51. Generic Injectables Industrial Chain
 Figure 52. Generic Injectables Manufacturing Cost Structure
 Figure 53. Channels of Distribution (Direct Sales, and Distribution)
 Figure 54. Bottom-up and Top-down Approaches for This Report
 Figure 55. Data Triangulation
 Figure 56. Key Executives Interviewed

お見積>

サンプルお申込み>

今すぐ購入>

PDFダウンロード>

当社から購入のメリット
  • jiantou

    多言語（英語、日本語）のサンプル提供

  • jiantou

    プロフェッショナルな日本語翻訳を提供

  • jiantou

    請求書、クレジットカードでのお支払いが可能です

  • jiantou

    必要なチャプターやカスタマイズされたレポートの注文が可能

  • jiantou

    購入後、アナリストに直接連絡することができます

購入方法
shunxu

  • 必要な言語とバージョンのレポート選択

  • レポート要件と見積もり依頼

  • 電子メールによる注文

  • レポートの入手（英語版は2～4営業日、日本語版は8～10営業日）

  • クレジットカード決済、オフライン振込に対応（後払い可）

※当サイトに掲載されていない海外調査報告書も当社経由でご購入いただけますので、お問い合わせください。

※市場調査レポートの購入や市場調査をご希望の場合は、実績と信頼のある株式会社市場調査センターにお任せください。

*フォーチュン500企業は当社と緊密な協力関係を確立しています

クライアント様（例）
ご利用ガイド
利用規約よくあるご質問プライバシーポリシー支払い方法と購入ガイド
お電話でのお問い合わせ
email050-5840-2692 日本
email0081-50-5840-2692 グローバル
9:00-18:00 (土日・祝日を除く)
底部logo
Copyright 2016-2026 Global Reports著作権所有